Les médicaments dérives du sang rôle des pharmaciens hospitaliers dans la gestion des facteurs anti- hémophiliques

Abstract

The Stable blood products called the derived from blood since 1995.they have a great importance in compensating of constitutional or acquired deficiencies in plasma proteins, hence their very variable frequency of use. Anti-hemophilic factors VIII and IX are the most used in Algeria. Currently only developed countries which have almost exclusive rights to produce MDS. Hemophilia is a constitutional hemorrhagic disease with sex-linked recessive transmission characterized by spontaneous or prolonged bleeding due to a qualitative or quantitative deficiency of factor VIII (HEMOPHILIA A) or factor IX (HEMOPHILIA B) whose hemophilia A is more common as hemophilia B. This is a disease that is transmitted from female carriers to males. The objective of this work is to evaluate the cost of the dispensation of each of the FAH within the public establishments of the wilaya of Sétif. Our study is retrospective descriptive during the year 2020 which affects 50 hemophiliacs including 45 hemophiliacs A (25 patients treated with plasma factor VIII; 12 advate®; 9novoeight®) and 4 hemophiliacs B treated with factor IX. 68% of cases are severe forms under prophylactic treatment. For the calendar year 2020, the number of patients with hemophilia who received their treatment in public establishments in the wilaya of Sétif was estimated at 50 patients, with an average weight of 68 kg. The direct total annual costs (number of boxes or units consumed) of plasma factor VIII, advate®, Novoeigh®t, and factor IX were calculated at 52546585.00 DA, 80710017.10 DA, 24466332.36 DA, 19064062.62 DA respectively. The total annual burden of hemophilia A and B in 2020 for the public establishments of the wilaya is estimated at 157722934.46 DA / 19064062.62 DA respectively, of which the CHU -SETIF occupies first place in terms of expenditure for all factors. We hope that our results will contribute to patient support, resource allocation and management strategies in Algeria to better experience patients.